The European Commission has approved Sanofi and Regeneron’s Dupixent for the treatment of moderate-to-severe chronic spontaneous urticaria.
Marks Breyanzi’s fourth indication in Europe, adding to existing approvals for several aggressive B-cell lymphomas.
BioMed X has launched a new collaborative research project with AbbVie, hosted at the BioMed X Institute in New Haven, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback